To appraise the clinical and cost effectiveness of tildrakizumab within its marketing authorisation for treating moderate to severe plaque psoriasis.
 
Status In progress
Process STA pre-2018
ID number 1060

Provisional Schedule

Committee meeting: 2 22 January 2019
Expected publication 17 April 2019

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Almirall
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups British Association of Dermatologists
  British Society for Rheumatology
  Royal College of Physicians
  UK Clinical Pharmacy Association
Professional groups Psoriasis and Psoriatic Arthritis Alliance
  Psoriasis Association

Commentators

Comparator companies AbbVie (adalimumab)
  Accord Healthcare (methotrexate) not participating
  Actavis UK (acitretin) not participating
  Almirall (dimethyl fumarate)
  Biogen Idec (etanercept, infliximab) not participating
  Celgene (apremilast)
  Concordia International (methotrexate) not participating
  Eli Lilly (ixekizumab)
  Genus Pharmaceuticals (acitretin) not participating
  Hameln Pharmaceuticals (methotrexate) not participating
  Hospira UK (infliximab, methotrexate) not participating
  Janssen-Cilag (guselkumab, ustekinumab)
  Leo Pharma (brodalumab)
  Medac GmbH (methotrexate) not participating
  Merck Sharp & Dohme (infliximab)
  Mylan (ciclosporin) not participating
  Napp Pharmaceuticals (infliximab) not participating
  Nordic Pharma (methotrexate) not participating
  Novartis Pharmaceuticals (ciclosporin, secukinumab)
  Orion Pharma UK (methotrexate) not participating
  Pfizer (etanercept, methotrexate)
  Rosemont Pharmaceuticals (methotrexate) not participating
  Sandoz (etanercept, methotrexate) not participating
General commentators All Welsh Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
04 December 2018 - 04 January 2019 Appraisal consultation
06 November 2018 Committee meeting: 1
14 June 2018 Invitation to participate
05 December 2017 In progress, Referred as part of Batch 55.
25 May 2017 - 23 June 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance